Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma.

Saeki H, Hashizume A, Izumi H, Suzuki F, Ishi K, Nojima M, Maeda M, Hino O.

Oncol Lett. 2012 Oct;4(4):637-641. Epub 2012 Jul 11.

2.

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.

Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.

Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.

3.

Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.

Hagiwara Y, Hamada Y, Kuwahara M, Maeda M, Segawa T, Ishikawa K, Hino O.

Cancer Sci. 2008 Apr;99(4):666-70. doi: 10.1111/j.1349-7006.2008.00731.x. Epub 2008 Feb 24.

4.

Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.

Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Watanabe S, Hino O.

Oncol Rep. 2008 Dec;20(6):1375-80.

PMID:
19020717
5.

ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.

Ito T, Kajino K, Abe M, Sato K, Maekawa H, Sakurada M, Orita H, Wada R, Kajiyama Y, Hino O.

Oncol Rep. 2014 Jan;31(1):27-33. doi: 10.3892/or.2013.2803. Epub 2013 Oct 22.

6.

Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT).

Sakamoto Y, Dai N, Hagiwara Y, Satoh K, Ohashi N, Fukamachi K, Tsuda H, Hirose A, Nishimura T, Hino O, Ogata A.

J Toxicol Sci. 2010 Apr;35(2):265-70.

7.

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.

Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O.

Cancer Sci. 2006 Sep;97(9):928-32. Epub 2006 Jun 7.

8.

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Sato T, Suzuki Y, Mori T, Maeda M, Abe M, Hino O, Takahashi K.

Cancer Med. 2014 Oct;3(5):1377-84. doi: 10.1002/cam4.297. Epub 2014 Jul 10.

9.

ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.

Tajima K, Hirama M, Shiomi K, Ishiwata T, Yoshioka M, Iwase A, Iwakami S, Yamazaki M, Toba M, Tobino K, Sugano K, Ichikawa M, Hagiwara Y, Takahashi K, Hino O.

Anticancer Res. 2008 Nov-Dec;28(6B):3933-6.

10.

MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.

Segawa T, Hagiwara Y, Ishikawa K, Aoki N, Maeda M, Shiomi K, Hino O.

Biochem Biophys Res Commun. 2008 May 9;369(3):915-8. doi: 10.1016/j.bbrc.2008.02.114. Epub 2008 Mar 5.

PMID:
18328258
11.

Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.

Fukamachi K, Iigo M, Hagiwara Y, Shibata K, Futakuchi M, Alexander DB, Hino O, Suzui M, Tsuda H.

PLoS One. 2014 Oct 27;9(10):e111481. doi: 10.1371/journal.pone.0111481. eCollection 2014.

12.

C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma.

Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, Takahashi N, Kamiyama T, Nishihara H, Taketomi A, Todo S.

J Gastroenterol. 2014 Jan;49(1):81-92. doi: 10.1007/s00535-013-0773-6. Epub 2013 Mar 20.

PMID:
23512344
13.

Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.

Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M, Hino O.

Pathol Int. 2009 Mar;59(3):161-6. doi: 10.1111/j.1440-1827.2009.02344.x.

PMID:
19261093
14.

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.

Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M.

Clin Cancer Res. 2006 Jan 15;12(2):447-53.

15.

Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.

Maeda M, Hino O.

Pathol Int. 2006 Nov;56(11):649-54. Review.

PMID:
17040286
16.

Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Mundt F, Nilsonne G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A.

PLoS One. 2013 Aug 21;8(8):e72030. doi: 10.1371/journal.pone.0072030. eCollection 2013.

17.

Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs.

Takata A, Yamauchi H, Toya T, Miyamoto-Kohno S, Iwatatsu Y, Teranaka I, Aminaka M, Yamashita K, Kohyama N.

Toxicol Appl Pharmacol. 2011 Apr 15;252(2):123-9. doi: 10.1016/j.taap.2010.09.026. Epub 2010 Oct 8.

PMID:
20933535
18.

Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin.

Nakaishi M, Kajino K, Ikesue M, Hagiwara Y, Kuwahara M, Mitani H, Horikoshi-Sakuraba Y, Segawa T, Kon S, Maeda M, Wang T, Abe M, Yokoyama M, Hino O.

Cancer Sci. 2007 May;98(5):659-64.

19.

Suppression of cell death by the secretory form of N-terminal ERC/mesothelin.

Wang T, Kajino K, Abe M, Tan K, Maruo M, Sun G, Hagiwara Y, Maeda M, Hino O.

Int J Mol Med. 2010 Aug;26(2):185-91.

PMID:
20596597
20.

Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.

Inami K, Abe M, Takeda K, Hagiwara Y, Maeda M, Segawa T, Suyama M, Watanabe S, Hino O.

Cancer Sci. 2010 Apr;101(4):969-74. doi: 10.1111/j.1349-7006.2009.01463.x. Epub 2009 Dec 9.

Supplemental Content

Support Center